Shiyuan Lu

1.2k total citations
25 papers, 363 citations indexed

About

Shiyuan Lu is a scholar working on Molecular Biology, Genetics and Surgery. According to data from OpenAlex, Shiyuan Lu has authored 25 papers receiving a total of 363 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Genetics and 5 papers in Surgery. Recurrent topics in Shiyuan Lu's work include Inflammatory Bowel Disease (7 papers), Nutritional Studies and Diet (4 papers) and Cancer-related molecular mechanisms research (4 papers). Shiyuan Lu is often cited by papers focused on Inflammatory Bowel Disease (7 papers), Nutritional Studies and Diet (4 papers) and Cancer-related molecular mechanisms research (4 papers). Shiyuan Lu collaborates with scholars based in China, Hong Kong and Sweden. Shiyuan Lu's co-authors include Jie Chen, Xue Li, Shuai Yuan, Xixian Ruan, Yuhao Sun, Jing‐Yuan Fang, Yun Qian, Shixian Hu, Antao Xu and Feng Fang and has published in prestigious journals such as Diabetes Care, Gut and Journal of Nutrition.

In The Last Decade

Shiyuan Lu

23 papers receiving 359 citations

Peers

Shiyuan Lu

GENET

IMMUN

ONCOL

Wanwei Zheng China

Anna Prossomariti Italy

Gilat Efroni Israel

Juliana Alves de Camargo Brazil

Qiu Yan China

Yugang Huang China

Risheng Cao China

Ailin Lu China

Die Yu China

Wanwei Zheng China

Shiyuan Lu

221 ×1.1

98 ×0.9

38 ×0.7

GENET

62 ×1.4

IMMUN

37 ×0.9

ONCOL

Citations per year, relative to Shiyuan Lu Shiyuan Lu (= 1×) peers Wanwei Zheng

Countries citing papers authored by Shiyuan Lu

Since Specialization

Citations

This map shows the geographic impact of Shiyuan Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shiyuan Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shiyuan Lu more than expected).

Fields of papers citing papers by Shiyuan Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shiyuan Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shiyuan Lu. The network helps show where Shiyuan Lu may publish in the future.

Co-authorship network of co-authors of Shiyuan Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Shiyuan Lu. A scholar is included among the top collaborators of Shiyuan Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shiyuan Lu. Shiyuan Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fan, Yihong, et al.. (2025). Ability of ChatGPT to Replace Doctors in Patient Education: Cross-Sectional Comparative Analysis of Inflammatory Bowel Disease. Journal of Medical Internet Research. 27. e62857–e62857. 4 indexed citations

Chen, Jie, Xixian Ruan, Tian Fu, et al.. (2024). Sedentary lifestyle, physical activity, and gastrointestinal diseases: evidence from mendelian randomization analysis. EBioMedicine. 103. 105110–105110. 22 indexed citations

Fu, Tian, Yuhao Sun, Shiyuan Lu, et al.. (2024). Risk Assessment for Gastrointestinal Diseases via Clinical Dimension and Genome-Wide Polygenic Risk Scores of Type 2 Diabetes: A Population-Based Cohort Study. Diabetes Care. 47(3). 418–426. 3 indexed citations

Wang, Tianyu, Shiyuan Lu, Yuhao Sun, et al.. (2024). Higher Dietary Quercetin Intake Is Associated with Lower Risk of Adverse Outcomes among Individuals with Inflammatory Bowel Disease in a Prospective Cohort Study. Journal of Nutrition. 154(6). 1861–1868. 5 indexed citations

Chen, Zhen, Jia Luo, Yongfu Yu, et al.. (2024). P416 Turning Point: Declining surgery rates and predictors for surgery in a three-year prospective inception cohort of Crohn's Disease in China. Journal of Crohn s and Colitis. 18(Supplement_1). i850–i852. 1 indexed citations

Chen, Jie, Yuhao Sun, Tian Fu, et al.. (2023). Risk of incident cardiovascular disease among patients with gastrointestinal disorder: a prospective cohort study of 330 751 individuals. European Heart Journal - Quality of Care and Clinical Outcomes. 10(4). 357–365. 6 indexed citations

Lu, Shiyuan, Shukui Qin, Kangsheng Gu, et al.. (2023). Bevacizumab biosimilar candidate TAB008 compared to Avastin® in patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter study. Journal of Cancer Research and Clinical Oncology. 149(9). 5907–5914. 2 indexed citations

Fu, Tian, Shiyuan Lu, Yuhao Sun, et al.. (2023). Adiposity as a risk factor for inflammatory bowel disease and the mediating effect of metabolic and inflammatory status: A population‐based cohort study. United European Gastroenterology Journal. 11(10). 973–984. 8 indexed citations

Chen, Jie, Xixian Ruan, Yuhao Sun, et al.. (2023). Multi-omic insight into the molecular networks of mitochondrial dysfunction in the pathogenesis of inflammatory bowel disease. EBioMedicine. 99. 104934–104934. 52 indexed citations

10.

Hou, Yichao, Xintian Zhang, Han Yao, et al.. (2023). METTL14 modulates glycolysis to inhibit colorectal tumorigenesis in p53‐wild‐type cells. EMBO Reports. 24(4). e56325–e56325. 43 indexed citations

11.

Li, Xiao, Qiao Yu, Shuyan Li, et al.. (2023). Impact of the first wave of COVID-19 on Crohn’s disease after the end of “zero-COVID” policy in China. Frontiers in Public Health. 11. 1186275–1186275. 2 indexed citations

12.

Lu, Shiyuan, et al.. (2022). LBA6 Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer: A multicentre, open-label, randomized phase III study. Annals of Oncology. 33. S1553–S1553.

13.

Lu, Shiyuan, et al.. (2022). 111P Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours. Annals of Oncology. 33. S83–S84. 1 indexed citations

14.

Wang, Yingchao, Xiao-Xu Leng, Cheng‐Bei Zhou, et al.. (2022). Non-enzymatic role of SOD1 in intestinal stem cell growth. Cell Death and Disease. 13(10). 882–882. 8 indexed citations

15.

Lu, Shiyuan, et al.. (2022). 138P Randomized phase III study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC): RATIONALE-304 updated analysis. Immuno-Oncology Technology. 16. 100250–100250. 1 indexed citations

16.

Ai, Luoyan, Mingming Zhu, Shiyuan Lu, et al.. (2021). Synbindin restrains proinflammatory macrophage activation against microbiota and mucosal inflammation during colitis. Gut. 70(12). 2261–2272. 42 indexed citations

17.

Yan, Tingting, Chaoqin Shen, Penglei Jiang, et al.. (2021). Risk SNP-induced lncRNA-SLCC1 drives colorectal cancer through activating glycolysis signaling. Signal Transduction and Targeted Therapy. 6(1). 70–70. 46 indexed citations

18.

Cui, Yun, Shiyuan Lu, Jie Xu, et al.. (2019). Microscopic features of small bowel mucosa of patients with Crohn’s disease. BMC Gastroenterology. 19(1). 232–232. 12 indexed citations

19.

Yu, Lei, et al.. (2017). lncRNA-HIT promotes cell proliferation of non-small cell lung cancer by association with E2F1. Cancer Gene Therapy. 24(5). 221–226. 42 indexed citations

20.

Hu, Zhigang, Bo-Ying Chen, Jianbin Tong, Dawei Huang, & Shiyuan Lu. (1993). The Change of C-Fos Expression in Ovariectomized Rats following Electroacupuncture Treatment—An Immunohistochemistry Study. Acupuncture & Electro-Therapeutics Research. 18(2). 117–124. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact